Bonus Material-31_Lung Cancer Part II_Silvestri2024

Pdf Summary

This comprehensive lung cancer board review by Dr. Gerard A. Silvestri covers invasive staging, treatment modalities across cancer stages, targeted therapies, and management of immune-related adverse events.<br /><br />Invasive staging techniques including mediastinoscopy, EBUS, EUS, and VATS are essential for mediastinal lymph node assessment, with PET and CT showing variable sensitivity and specificity. The 2013 ACCP guidelines recommend needle-based techniques like EBUS/EUS as first-line invasive staging in suspected N2/N3 disease.<br /><br />For Stage I non-small cell lung cancer (NSCLC), lobectomy with mediastinal node dissection remains standard, with video-assisted thoracic surgery (VATS) favored for less morbidity and faster recovery versus open lobectomy. Sublobar resections show comparable survival but slightly higher local recurrence in stage IA tumors ≤2cm. For medically inoperable patients, stereotactic body radiotherapy (SBRT) offers high-precision ablative treatment with fewer toxicities than conventional radiation.<br /><br />Stage II disease treatment includes surgery combined with adjuvant chemotherapy or targeted therapy for EGFR/ALK mutations, or neoadjuvant chemoimmunotherapy followed by surgery if negative for these mutations. Pancoast tumors require multimodality treatment with induction chemoradiotherapy and en bloc resection when possible.<br /><br />Stage IIIA disease may be treated with chemoradiotherapy plus adjuvant immunotherapy, neoadjuvant chemoimmunotherapy followed by surgery, or targeted therapy (osimertinib for EGFR, alectinib for ALK). The PACIFIC trial supports durvalumab consolidation after chemoradiation for unresectable disease, significantly improving progression-free survival.<br /><br />Stage IV NSCLC treatment is guided by molecular markers such as EGFR, ALK, ROS1, PD-L1, and others. Targeted therapies tailored to mutations (e.g., osimertinib for EGFR, alectinib for ALK) and immunotherapy improve outcomes. Small cell lung cancer (SCLC) management differs, with cisplatin-etoposide chemo and immunotherapy for extensive disease and chemoradiation for limited disease. Prophylactic cranial irradiation (PCI) reduces CNS metastases risk in responders.<br /><br />Immune-related adverse events (IRAEs) from checkpoint inhibitors require graded management, ranging from observation to corticosteroids and therapy discontinuation in severe cases.<br /><br />Overall, this review emphasizes precision medicine, balancing surgical, systemic, and radiation approaches based on stage, molecular profile, and patient fitness to optimize lung cancer outcomes.

Meta Tag

Concept Mediastinal Staging

Concept Small Cell Lung Cancer

Concept Non-Small Cell Lung Cancer

Concept Pancoast Tumor

Concept Lymph Node Biopsy

Keywords

lung cancer

non-small cell lung cancer

invasive staging

EBUS

mediastinoscopy

lobectomy

SBRT

targeted therapy

immunotherapy

immune-related adverse events

Mediastinal Staging

Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Pancoast Tumor

Lymph Node Biopsy